Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Colecchia
Observed name:
Maurizio Colecchia
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele
Observed institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele
ORCID:
0000-0003-1914-0743
Observed ORCID:
0000-0003-1914-0743
OpenAlex ID:
A5125939202
Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression
2026
·
Arianna Brevi
, Marco Lorenzoni
, et al.
·
Cancer Research
·
2
Comprehensive Genomic Profiling (CGP) of clinical T2-4N0M0 Muscle-Invasive Bladder Cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before Radical Cystectomy (RC)
2024
·
C. Mercinelli
, D. Raggi
, et al.
·
European Urology
·
1
4791eP Outcomes and characteristics of patients with muscle-invasive bladder cancer (MIBC) enrolled in perioperative therapy trials and radical cystectomy (RC) at San Raffaele Comprehensive Cancer Center
2026
·
B.A. Maiorano
, D. Serafin
, et al.
·
Annals of Oncology
4759P Outcomes of patients with muscle-invasive bladder cancer (MIBC) who declined radical cystectomy (RC) in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center
2026
·
C. Mercinelli
, G. Basile
, et al.
·
Annals of Oncology
P0852 Can mpMRI and PSMA PET predict contralateral clinically significant prostate cancer at biopsy and radical prostatectomy? Implications for focal therapy candidate selection
2026
·
P. Scilipoti
, A. Stabile
, et al.
·
European Urology
A0820 How reliable is intraoperative judgment during TURBT? An inter-observer concordance analysis across key surgical parameters
2026
·
P. Scilipoti
, M. De Angelis
, et al.
·
European Urology
A0587 Non-luminal molecular subtypes demonstrate highest complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo & BLASST-01 phase 2 clinical trials
2026
·
J.J. De Jong
, C. Mercinelli
, et al.
·
European Urology
P0164 Positive surgical margins after partial nephrectomy: Still a real concern or a fading threat?
2026
·
A. Bertini
, C. Re
, et al.
·
European Urology
P0783 The diagnostic benefit of perilesional sampling at the time of confirmatory biopsy in patients managed with active surveillance for isup-gg 1 prostate cancer
2026
·
L. Quarta
, R. Leni
, et al.
·
European Urology
P0205 Recurrence-free survival after Checklist adoption in non-muscle invasive bladder cancer: insights from a single-center experience
2026
·
A. Occhi
, M. De Angelis
, et al.
·
European Urology
P0854 Prostate MRI quality strongly influences the diagnostic yield of systematic and targeted biopsies: Insights from a prospective study
2026
·
M. Longoni
, P. Scilipoti
, et al.
·
European Urology
A0747 Outcomes and treatment patterns of prostate cancer patients with low risk biochemical recurrence after radical prostatectomy managed with initial observation
2026
·
F. Barletta
, A. Stabile
, et al.
·
European Urology
P0779 Favorable grade group 1 prostate cancer at confirmatory biopsy: Toward personalized active surveillance follow-up strategies
2026
·
R. Leni
, A. Stabile
, et al.
·
European Urology
P0950 Development of a transcriptome-based model for predicting adverse pathology at radical cystectomy
2026
·
A. Viti
, P. Scilipoti
, et al.
·
European Urology
A0599 Purinergic signaling modulation: A novel promising therapeutic strategy for prostate cancer
2026
·
A. Viti
, A. Stabile
, et al.
·
European Urology
A0475 Refining surveillance for small renal masses: Predicting aggressiveness and oncologic outcomes based on tumour size and patient characteristics
2026
·
L. Salerno
, F. Cei
, et al.
·
European Urology
A0490 The impact of PI-QUAL score on diagnostic and economic efficiency of mpMRI for prostate cancer: Results from a prospective evaluation of external scans after central review
2026
·
M. Longoni
, P. Scilipoti
, et al.
·
European Urology
P0778 Predictors of progression during active surveillance for grade group 1 prostate cancer in the mpMRI era: Implications for follow-up strategies
2026
·
R. Leni
, A. Stabile
, et al.
·
European Urology
A0476 When silence speaks loud: Decoding symptomatic presentation in small renal masses
2026
·
A. Bertini
, C. Re
, et al.
·
European Urology
A0395 Epigenetic profiling reveals divergent methylation landscapes in MRI-targeted and systematic biopsy prostate cancer
2026
·
M. Bandini
, F.M. Barletta
, et al.
·
European Urology
P0216 Nomogram for predicting tumor persistence at second-look TURBT in non–muscleinvasive bladder cancer
2026
·
M. De Angelis
, M. Brancaccio
, et al.
·
European Urology
Tumor Mutational Burden (TMB) predicts the outcome of patients (pts) with Muscle-Invasive Bladder Cancer (MIBC) undergoing Immune-Checkpoint Inhibitor (ICI)-based neoadjuvant therapy
2025
·
C. Mercinelli
, G. Basile
, et al.
·
European Urology Open Science
P548 – Epigenetic profiling of multifocal prostate cancer: Methylation differences between mpMRI-visible and invisible lesions
2025
·
M. Bandini
, A.S. Tascini
, et al.
·
European Urology
2024TiP NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring
2024
·
V. Tateo
, A. Cigliola
, et al.
·
Annals of Oncology
PDF
Clinical characteristics and oncologic outcomes of bladder neuroendocrine carcinoma in a contemporary, multi-institutional cohort
2024
·
E. Zaffuto
, R. Leni
, et al.
·
European Urology
Show more works
View as search
Works count:
40
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type